GLP-1 & Incretin Science

When the Intended Effect Goes Too Far

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Olubodun and colleagues published a systematic review of gastroparesis induced by GLP-1 receptor agonists in PLoS One in 2026, describing clinical features, diagnosis, management and outcomes, and characterising it as an under-recognised but clinically important complication.

Key facts

Systematic review
Olubodun 2026 (PMID 42594084)
Journal
PLoS One
Described as
Under-recognised but clinically important
Covers
Features, diagnosis, management, outcomes
Case report
Singhal 2025 (PMID 41054677)
Implicated factor
Rapid dose escalation

What gastroparesis is

Delayed gastric emptying severe enough to cause symptoms in the absence of mechanical obstruction: nausea, vomiting, early fullness, bloating and sometimes weight loss. It is defined by the combination of measurably slow emptying and symptoms attributable to it, not by slow emptying alone.

Why this class produces it

Because delaying gastric emptying is part of how these drugs work. Prolonging fullness and blunting the post-meal glucose rise are intended effects, and they are produced by the same slowing that, taken far enough, becomes the condition. The complication is the mechanism at an extreme rather than an unrelated toxicity.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why that makes the boundary hard to draw

There is no clean line between intended effect and complication when both are the same physiological change. Reduced appetite and early fullness are the point of the treatment and are also gastroparesis symptoms. Distinguishing them depends on severity, persistence and whether the person can maintain adequate intake, which is a clinical judgement rather than a measurement.

The dose escalation observation

Singhal and colleagues reported a case in Cureus in 2025 framed explicitly around the dangers of rapid dose escalation. That is mechanistically coherent: the emptying delay is largest when a dose is new and attenuates with continued exposure, so moving quickly through doses reintroduces the strongest effect repeatedly rather than allowing adaptation.

Why a systematic review matters for a complication like this

Case reports establish that something happens; they cannot say how often or in whom. Pooling them systematically produces a description of typical features, how the diagnosis is reached and what happens subsequently. For an under-recognised complication that is the necessary first step. Before frequency can be estimated, the entity has to be characterised.

What this concerns

Licensed medicines prescribed and monitored clinically, and published clinical literature about them. Nothing supplied on this site is a GLP-1 receptor agonist, affects gastric emptying, or has any bearing on the care of any person.

Frequently asked questions

Why do GLP-1 drugs cause it?

Delaying gastric emptying is part of how they work. The complication is that intended mechanism taken to an extreme.

What does dose escalation have to do with it?

The emptying delay is largest when a dose is new and attenuates with continued exposure, so rapid escalation reintroduces the strongest effect repeatedly.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.